Article Sidebar
Published:
Jun 25, 2020Keywords:
Sclerosing epithelioid fibrosarcoma; surgery; adjuvant treatment; recurrences; metastases
Article Details
Issue
Section
Articles
Brief summary of the agreement
Anyone is free:
· to copy, distribute, and display the work;
· to make derivative works;
· to make commercial use of the work;
Under the following conditions: Attribution
· the original author must be given credit;
· for any reuse or distribution, it must be made clear to others what the license terms of this work are;
· any of these conditions can be waived if the authors gives permission.
Statutory fair use and other rights are in no way affected by the above
Main Article Content
Sclerosing epithelioid fibrosarcoma: rare and serious
Abstract
Sclerosing Epithelioid Fibrosarcoma (SEF) is a rare form of soft tissue sarcoma. It is characterized by a slow evolution, with local recurrences and late metastases that are mainly pulmonary and pleural in about 50% of cases. The treatment is based on the surgery which must be as wide as possible. The efficacy of adjuvant therapy in the control of SEF is not yet demonstrated. Chemotherapy is used in recurrences, some have also proposed radiotherapy. Long-term follow-up of patients with SEF is therefore essential.
